268 related articles for article (PubMed ID: 26913438)
1. [Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].
Xu YY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):285-9. PubMed ID: 26913438
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic predictors of prognosis in myelodysplastic syndromes.
Bejar R
Haematologica; 2014 Jun; 99(6):956-64. PubMed ID: 24881041
[TBL] [Abstract][Full Text] [Related]
3. Prognostic models in myelodysplastic syndromes.
Bejar R
Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
[TBL] [Abstract][Full Text] [Related]
4. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
Nazha A; Bejar R
Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
[TBL] [Abstract][Full Text] [Related]
5. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
6. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
7. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
Greenberg PL
J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
[TBL] [Abstract][Full Text] [Related]
8. [A novel prognostic model incorporating genetic profiling for myelodysplastic syndromes].
Nagata Y; Ogawa S
Rinsho Ketsueki; 2017; 58(7):776-786. PubMed ID: 28781274
[TBL] [Abstract][Full Text] [Related]
9. [Molecular international prognostic scoring system for myelodysplastic syndromes].
Nagata Y
Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
[TBL] [Abstract][Full Text] [Related]
10. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
12. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
13. Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.
Yu Y; Zhang T; Bao X; Wang Q; Zhang L; Hong Y; Zeng Z; Shen H; Wu D; Pan J; Liu H; Chen S; Sun A
Leuk Lymphoma; 2020 Apr; 61(4):919-926. PubMed ID: 31842651
[TBL] [Abstract][Full Text] [Related]
14. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and risk models in myelodysplastic syndromes.
Komrokji RS; Padron E; Lancet JE; List AF
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S295-9. PubMed ID: 24290214
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
17. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics in myelodysplastic syndromes.
Haferlach T
Leuk Res; 2012 Dec; 36(12):1459-62. PubMed ID: 22986016
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.
Steensma DP
Best Pract Res Clin Haematol; 2017 Dec; 30(4):295-300. PubMed ID: 29156198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
